ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 31 March 2023
|
|
attaman123
|
102 |
37K |
4 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
102
|
37K
|
4
|
|
ASX - By Stock
|
PAB |
Cross BBB to deliver gene to CNS: AAV vs ADC
|
|
attaman123
|
0 |
561 |
21 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
0
|
561
|
21
|
|
ASX - By Stock
|
PAB |
Re:
Nature: Circular ecDNA promotes high oncogene expression
|
|
attaman123
|
5 |
3.9K |
2 |
24/11/19 |
24/11/19 |
ASX - By Stock
|
5
|
3.9K
|
2
|
|
ASX - By Stock
|
PAB |
Nature: Circular ecDNA promotes high oncogene expression
|
|
attaman123
|
5 |
3.9K |
16 |
23/11/19 |
23/11/19 |
ASX - By Stock
|
5
|
3.9K
|
16
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Updated investor presentation and attendance at Bioshares
|
|
attaman123
|
72 |
49K |
11 |
05/08/19 |
05/08/19 |
ASX - By Stock
|
72
|
49K
|
11
|
|
Charts
|
PAB |
Re:
PAB chart
|
|
attaman123
|
1.8K |
740K |
8 |
17/01/19 |
17/01/19 |
Charts
|
1.8K
|
740K
|
8
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 September 2018
|
|
attaman123
|
72 |
25K |
2 |
16/11/18 |
16/11/18 |
ASX - By Stock
|
72
|
25K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 September 2018
|
|
attaman123
|
72 |
25K |
1 |
02/11/18 |
02/11/18 |
ASX - By Stock
|
72
|
25K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 September 2018
|
|
attaman123
|
72 |
25K |
6 |
31/10/18 |
31/10/18 |
ASX - By Stock
|
72
|
25K
|
6
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Settlement of Manufacturing Claims
|
|
attaman123
|
15 |
5.9K |
7 |
25/10/18 |
25/10/18 |
ASX - By Stock
|
15
|
5.9K
|
7
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Clinical Target Indications Confirmed
|
|
attaman123
|
152 |
49K |
0 |
23/10/18 |
23/10/18 |
ASX - By Stock
|
152
|
49K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Investor Update
|
|
attaman123
|
8 |
3.9K |
10 |
28/09/18 |
28/09/18 |
ASX - By Stock
|
8
|
3.9K
|
10
|
|
ASX - By Stock
|
PAB |
Re:
Would Glioblastoma be the target indication?
|
|
attaman123
|
5 |
3.0K |
3 |
23/09/18 |
23/09/18 |
ASX - By Stock
|
5
|
3.0K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Happy Anniversary
|
|
attaman123
|
79 |
28K |
3 |
13/09/18 |
13/09/18 |
ASX - By Stock
|
79
|
28K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Happy Anniversary
|
|
attaman123
|
79 |
28K |
15 |
11/09/18 |
11/09/18 |
ASX - By Stock
|
79
|
28K
|
15
|
|
ASX - By Stock
|
PAB |
Re:
Would Glioblastoma be the target indication?
|
|
attaman123
|
5 |
3.0K |
5 |
04/08/18 |
04/08/18 |
ASX - By Stock
|
5
|
3.0K
|
5
|
|
ASX - By Stock
|
PAB |
Re:
Would Glioblastoma be the target indication?
|
|
attaman123
|
5 |
3.0K |
6 |
04/08/18 |
04/08/18 |
ASX - By Stock
|
5
|
3.0K
|
6
|
|
ASX - By Stock
|
PAB |
Would Glioblastoma be the target indication?
|
|
attaman123
|
5 |
3.0K |
2 |
02/08/18 |
02/08/18 |
ASX - By Stock
|
5
|
3.0K
|
2
|
|
ASX - By Stock
|
PAB |
nanocell or nanoparticle?
|
|
attaman123
|
2 |
2.0K |
3 |
15/07/18 |
15/07/18 |
ASX - By Stock
|
2
|
2.0K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Preliminary PAT-DX1 pharmacokinetics
|
|
attaman123
|
70 |
39K |
15 |
10/07/18 |
10/07/18 |
ASX - By Stock
|
70
|
39K
|
15
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Preliminary PAT-DX1 pharmacokinetics
|
|
attaman123
|
70 |
39K |
1 |
05/07/18 |
05/07/18 |
ASX - By Stock
|
70
|
39K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Preliminary PAT-DX1 pharmacokinetics
|
|
attaman123
|
70 |
39K |
2 |
05/07/18 |
05/07/18 |
ASX - By Stock
|
70
|
39K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: China and Japan both grant patents for Deoxymab 3E10
|
|
attaman123
|
18 |
8.8K |
2 |
04/07/18 |
04/07/18 |
ASX - By Stock
|
18
|
8.8K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Litigation
|
|
attaman123
|
8 |
5.5K |
2 |
02/06/18 |
02/06/18 |
ASX - By Stock
|
8
|
5.5K
|
2
|
|
ASX - By Stock
|
PAB |
A few thoughts on Patrys' current work and DX1's future path
|
|
attaman123
|
7 |
4.1K |
5 |
28/04/18 |
28/04/18 |
ASX - By Stock
|
7
|
4.1K
|
5
|
|
Charts
|
PAB |
Re:
PAB chart
|
|
attaman123
|
1.8K |
740K |
1 |
21/04/18 |
21/04/18 |
Charts
|
1.8K
|
740K
|
1
|
|
Charts
|
PAB |
Re:
PAB chart
|
|
attaman123
|
1.8K |
740K |
4 |
13/04/18 |
13/04/18 |
Charts
|
1.8K
|
740K
|
4
|
|
Charts
|
PAB |
Re:
PAB chart
|
|
attaman123
|
1.8K |
740K |
13 |
01/04/18 |
01/04/18 |
Charts
|
1.8K
|
740K
|
13
|
|
Charts
|
PAB |
Re:
PAB chart
|
|
attaman123
|
1.8K |
740K |
14 |
23/03/18 |
23/03/18 |
Charts
|
1.8K
|
740K
|
14
|
|
ASX - By Stock
|
PAB |
Re:
Enhanced Brain Cancer survival rates
|
|
attaman123
|
15 |
5.5K |
2 |
19/03/18 |
19/03/18 |
ASX - By Stock
|
15
|
5.5K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Improves Survival in Animal Model of Glioblastoma
|
|
attaman123
|
21 |
11K |
1 |
19/03/18 |
19/03/18 |
ASX - By Stock
|
21
|
11K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size
|
|
attaman123
|
167 |
78K |
7 |
17/03/18 |
17/03/18 |
ASX - By Stock
|
167
|
78K
|
7
|
|
ASX - By Stock
|
PAB |
Re:
Potential Glioma treatment
|
|
attaman123
|
4 |
3.2K |
12 |
11/03/18 |
11/03/18 |
ASX - By Stock
|
4
|
3.2K
|
12
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size
|
|
attaman123
|
167 |
78K |
8 |
10/03/18 |
10/03/18 |
ASX - By Stock
|
167
|
78K
|
8
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size
|
|
attaman123
|
167 |
78K |
2 |
06/03/18 |
06/03/18 |
ASX - By Stock
|
167
|
78K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size
|
|
attaman123
|
167 |
78K |
4 |
06/03/18 |
06/03/18 |
ASX - By Stock
|
167
|
78K
|
4
|
|
Charts
|
PAB |
Re:
PAB chart
|
|
attaman123
|
1.8K |
740K |
20 |
03/03/18 |
03/03/18 |
Charts
|
1.8K
|
740K
|
20
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Targets Nanoparticles to Breast Cancer
|
|
attaman123
|
34 |
16K |
4 |
29/01/18 |
29/01/18 |
ASX - By Stock
|
34
|
16K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Trading Halt
|
|
attaman123
|
30 |
11K |
5 |
11/01/18 |
11/01/18 |
ASX - By Stock
|
30
|
11K
|
5
|
|
ASX - By Stock
|
PAB |
Re:
Ann: NDF Research - Initiation of Coverage
|
|
attaman123
|
9 |
3.7K |
5 |
28/12/17 |
28/12/17 |
ASX - By Stock
|
9
|
3.7K
|
5
|
|
ASX - By Stock
|
PAB |
Re:
is it worth ten cents ?
|
|
attaman123
|
2 |
1.6K |
2 |
23/12/17 |
23/12/17 |
ASX - By Stock
|
2
|
1.6K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Reminder of this exciting discovery
|
|
attaman123
|
26 |
10K |
0 |
02/10/17 |
02/10/17 |
ASX - By Stock
|
26
|
10K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Reminder of this exciting discovery
|
|
attaman123
|
26 |
10K |
4 |
29/09/17 |
29/09/17 |
ASX - By Stock
|
26
|
10K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAB Business Review - 30 June 2017
|
|
attaman123
|
10 |
4.7K |
4 |
26/09/17 |
26/09/17 |
ASX - By Stock
|
10
|
4.7K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
|
|
attaman123
|
122 |
48K |
3 |
21/09/17 |
21/09/17 |
ASX - By Stock
|
122
|
48K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
|
|
attaman123
|
122 |
48K |
1 |
20/09/17 |
20/09/17 |
ASX - By Stock
|
122
|
48K
|
1
|
|
ASX - By Stock
|
PAB |
SP to hit a new low?
|
|
attaman123
|
2 |
1.6K |
0 |
13/09/17 |
13/09/17 |
ASX - By Stock
|
2
|
1.6K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAB Licences Deoxymab 3E10 - nanoparticle IP from Yale
|
|
attaman123
|
3 |
2.3K |
8 |
04/09/17 |
04/09/17 |
ASX - By Stock
|
3
|
2.3K
|
8
|
|
ASX - By Stock
|
PAB |
Re:
Annual report
|
|
attaman123
|
4 |
1.7K |
4 |
01/09/17 |
01/09/17 |
ASX - By Stock
|
4
|
1.7K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Annual report
|
|
attaman123
|
4 |
1.7K |
4 |
30/08/17 |
30/08/17 |
ASX - By Stock
|
4
|
1.7K
|
4
|
|